Till Wallrabenstein (T Wallrabenstein)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Systematic Review

Metastatic Breast Cancer

Rheumatoid Arthritis Patients

Top Venues

Journal for immunotherapy of cancer

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Till Wallrabenstein, Anton Oseledchyk, Eveline Daetwyler, Christoph Rochlitz, Marcus Vetter
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane-PLD versus PLD-Taxane in Patients with Metastatic Breast Cancer. Cancers 15 (20) (2023)
Till Wallrabenstein, E Daetwyler, A Oseledchyk, C Rochlitz, M Vetter
Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer. Cancer medicine (2023)